System secures US$20 million as peptide wellness market accelerates
Key takeaways
- System has raised US$20 million to expand its vertically integrated peptide platform and improve access to peptide treatments.
- Recent FDA advisory recommendations could reshape injectable peptide access, but formal approval is still pending.
- Growing interest in longevity and wellness is driving demand for peptide-based health care solutions.
System, a wellness platform that connects consumers with clinicians, has secured US$20 million to solidify its foothold in the rapidly growing peptide industry. The peptide-native platform’s funding arrives as the broader peptide market is projected to reach US$163 billion in 2026, according to System.
The platform says the procured capital will make injectable peptide treatments that have traditionally been exclusive to “a select group of patients” more accessible to broader demographics.
“Despite a rising adoption of the longevity drugs known to support everything from anti-aging and skin rejuvenation to weight loss management, muscle growth, recovery, and energy enhancement, peptides have historically been costly, unregulated, and largely inaccessible,” says the company.
However, on July 23–24, the US Food & Drug Administration (FDA) voted to recommend adding six previously unapproved injectable peptides to a bulk drug substance list, which could eventually allow licensed compounding pharmacies to produce them if the FDA adopts the recommendations.
With the vote, System says that peptides are moving toward a more regulated, legitimate distribution model that aligns with growing consumer interest.
“Peptides are moving from the edges of wellness into mainstream consumer culture. As health care becomes more personal, and increasingly part of how people express their identity, the category-defining companies will be built by founders who understand that trust, quality, and brand are inseparable,” says Amber Atherton, partner at Patron Fund.
System’s new funding was sourced from Patron Fund, Will Ventures, Vine, Courtside, Daybreak, SV Angel, and RiverPark Ventures.
Peptide politics
System positions itself as working toward the infrastructure peptide supply chains as the ingredient enters a new phase of regulation and access.
Peptide-based treatments gain attention amid shifting regulatory discussions.
The platform pairs consumers with US-licensed clinicians who evaluate individual health history and prescribe personalized peptide protocols. The company claims to differentiate itself from other suppliers and clinicians in the market through its end-to-end supply chain model.
“System takes ownership by acquiring every link in the peptide supply chain, with a compounding pharmacy in its network and a raw-ingredient manufacturer on its roadmap,” says the company.
According to System, its operating model is “highly transparent” as patients and regulators are able to view details of all products and transactions.
Set across an industry backdrop in which the reliability of injectable peptides and their lack of sufficient clinical research for human usage is highly debated, System maintains its position through an appeal to clinical backing.
“Every product is third-party lab tested, clinicians are background-checked and NPDB-reviewed (National Practitioner Data Bank), and each treatment is sourced through FDA-registered US compounding pharmacies,” says System.
“We want to be category definers and the solution Americans use and trust for their long-term health. This funding signals that we’re building a company that is filling the gap between concierge clinics and research-grade access that no single platform currently owns,” says Adam Steinle, founder and CEO of System.
Injectable peptide contention
Personal Care Insights previously reported on what the impact could be on the personal care industry if injectable peptide compounds gain wider regulatory acceptance.
“For the personal care industry, the key question will be whether companies communicate responsibly,” Leigh Verbois, Alliance for Safe Online Pharmacies global board chair and former director of the Office of Drug Security, Integrity, and Response at the US FDA, told us.
Peptides have been a staple of the beauty industry, used in topical skin care solutions for decades, but injectables have recently garnered public attention due to social media’s boasting about their “beneficial” effects. “Wellness” influencers claim they have longevity properties, such as anti-aging and skin rejuvenation.
At the time of the vote, the FDA’s own scientists discouraged the approval of the seven injectable solutions. It did so on the basis of insufficient safety and efficacy and limited human studies.
